Medivir Ab Stock Quote 0GP7 - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

41.70

Bid

0.00

Ask

0.00

Volume

0.00

0.00 Day's Range 0.00

41.70 52 Week Range 41.70

Market Cap

4.394B

Previous Close

41.70

Open

Last Trade

(O)

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

0.00

Shares Outstanding

105,371,000

Dividend Yield

PE Ratio

-0.97

Earnings Per Share (EPS)

-0.85

Revenue

7.66M

Net Profit

-89.32M

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Diversified

Website

www.medivir.se

Headquarters

Huddinge, Swe

Founded

1992

Medivir Ab is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker 0GP7. The last closing price for Medivir Ab was SEK41.70. Over the last year, Medivir Ab shares have traded in a share price range of SEK 41.70 to SEK 41.70.

Medivir Ab currently has 105,371,000 shares outstanding. The market capitalization of Medivir Ab is SEK4.39 billion. Medivir Ab has a price to earnings ratio (PE ratio) of -0.97.

Medivir to present clinical pharmacokinetic data at EASL Liver Cancer Summit, further supporting the continued development of fostrox

Medivir to present clinical pharmacokinetic data at EASL Liver Cancer Summit, further supporting the continued development of fostrox PR Newswire STOCKHOLM, Jan. 15, 2024 STOCKHOLM, Jan. 15, 2024...

Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study

Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study PR Newswire STOCKHOLM, Jan. 4, 2024 STOCKHOLM, Jan. 4, 2024...

Fostrox + Lenvima demonstrates further improvement in durable clinical benefit in HCC, supporting the accelerated development plan

Fostrox + Lenvima demonstrates further improvement in durable clinical benefit in HCC, supporting the accelerated development plan PR Newswire STOCKHOLM, Dec. 19, 2023 Sustained disease control...

Medivir have agreed with Lonza to manufacture a fostrox GMP campaign, to be tested in 2L HCC with intent to commercialize via accelerated approval

Medivir have agreed with Lonza to manufacture a fostrox GMP campaign, to be tested in 2L HCC with intent to commercialize via accelerated approval PR Newswire STOCKHOLM, Dec. 13, 2023 STOCKHOLM...

Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC

Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC PR Newswire STOCKHOLM, Nov. 27, 2023 STOCKHOLM, Nov. 27...

Period	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	DE
4	0	0	0	0	0	DE
12	0	0	0	0	0	DE
26	41.7	41.7	41.7	1952	41.7	DE
52	41.7	41.7	41.7	2316	41.7	DE
156	41.7	41.7	41.7	1427	41.7	DE
260	41.7	41.7	41.7	4535	41.7	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
SHIMShimmick Corporation	$ 3.17 (53.14%)	1.55M
MLGOMicroAlgo Inc	$ 3.44 (21.13%)	4.49M
ADVMAdverum Biotechnologies Inc	$ 10.78 (20.85%)	311.76k
AFARUAura FAT Projects Acquisition Corporation	$ 14.74 (19.55%)	992
ALSAAlpha Star Acquisition Corporation	$ 12.25 (17.22%)	9
FIVEFive Below Inc	$ 86.00 (-15.74%)	28.89k
QXOQXO Inc	$ 47.51 (-12.83%)	446
LRELead Real Estate Company Ltd	$ 1.84 (-12.38%)	8.69k
VRPXVirpax Pharmaceuticals Inc	$ 1.33 (-11.92%)	110.6k
CNVSCineverse Corporation	$ 0.80 (-10.11%)	700
APVOAptevo Therapeutics Inc	$ 0.378 (12.84%)	17.6M
CEROCERo Therapeutics Holdings Inc	$ 0.2139 (9.69%)	10.28M
CDTConduit Pharmaceuticals Inc	$ 0.2713 (8.04%)	6.13M
MLGOMicroAlgo Inc	$ 3.43 (20.77%)	4.49M
NVDANVIDIA Corporation	$ 122.33 (-3.19%)	2.69M